Mark Massaro: Okay. Great. And then, Reg, maybe just to clarify, did I hear you say that the underlying volume growth in transplant is, call it, around negative 3% here in Q1? And I know that you’ve called out a number of drivers to the challenging end market, things like staffing shortages, living donor transplant changes. I think a lot of the items that you call as potential benefits to the volumes. Many of those appear to be kind of multiyear drivers over time. I’m just curious if you see any short-term potential changes with respect to staffing shortages, for instance, is maybe one, but what are something that you guys can actively do to manage this in the near term?
Reginald Seeto: It’s really interesting this whole market dynamic. And I think we — as you can see in the prepared slides as part of the webcast, I mean you’d seen this increase in Q2 of last year of going to 6% and 4%, then 2% sequential. But then year-to-date on 7 quarters, 7 weekly data, minus 3 across the total, but each organ group has had a decline. So that hasn’t gone the way that we had expected. But that said, I do think the drivers and all the are there I meet with transplant centers every week, Mark, and I asked him the same question to see what’s happening as well from their viewpoint. And there’s been various answers, but some of the consistent ones are definitely the living donors is not rebounded and staffing shortages means that they can’t always do procedures as they’d like to.
And this is line that’s seen across all groups as well. We do have seen an increase in the C stone as though, for example, on the kidney side. So I think at the end of the day, some of the different areas that you described, they will happen faster than later in terms of the drivers. So if you talk about the transportation or perfusion devices, for example, that expands the pool patients. So for example, in heart, strifly , it’s been what you call DVD or brain-dead donors, but now you’ve expanded the pool by adding the C stone, which is triple hadn’t been there. And even recently as CEO on the weekend, I talked to one center, which has increased the number of transplant they plan to do on the hard side, for example, by using this alternative approach of using ceased organ.
So I do think that there will be changes that you start seeing hopefully sooner rather than later. I do think living donors, however, is the biggest beta. The biggest driver of delta that 1 could achieve during that time period. And I do think the government initiatives will put in actually enforce that donation, transplantation rate and really forces the whole ecosystem to play together. So I do think those unifying factors will play a role. But you’re right, it will be a different cadence, probably the — expanding the donor pool is the first one. Then over time, I think some of those government initiatives will kick in quite nicely.
Mark Massaro: Excellent. If I can sneak in one final two parter. How are you guys doing with respect to RemoTraC? I know that you used to hover around 40% of your volumes. And then finally, you guys have $293 million of cash. Historically you’ve done a great job of bolting on tuck-ins, sort of differentiating the product suite across your portfolio. You recently acquired HLA Data Systems. So how should we think about and you’re about to achieve adjusted EBITDA positivity. How should we think about M&A funnel? And what sorts of things are you potentially looking at?
